Compare Medpace Holdings Inc (MEDP) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Medpace Holdings Inc trades at $616.98 (market cap $17.02B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Medpace Holdings Inc is far larger — about 2.3× Spyre Therapeutics Inc. Common Stock's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MEDP | SYRE | |
|---|---|---|
Market Cap | $17.02B | $7.52B |
Volume | 155,250 | 1,441,031 |
Sector | Health | Health |
52-Week High | $630.19 | $108.92 |
52-Week Low | $393.42 | $22.18 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.63B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $609.89, down 1.64% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent news highlights CEO stock sales and institutional position adjustments, while Q3 2026 results are expected October 21, 2026.
MEDP offers growth potential with a consensus price target of $620.44 (1.7% upside), supported by projected 2026 revenue growth to $2.8B. Risks include high valuation multiples (P/E 35.82) and insider selling. Analyst sentiment is cautious with 78.95% hold ratings, suggesting limited near-term catalysts.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
